Dear PPTA Stakeholders,

PPTA is pleased to announce that, as of today, reporting of data on the U.S. supply of certain plasma protein therapies has resumed.

Dear PPTA Stakeholders,

PPTA's North America data program was established in 1998 in response to a specific recommendation of the Advisory Committee on Blood Safety and Availability (ACBSA).

ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) honored California State Assemblymember Toni Atkins (D) of San Diego as State Legislator of the Year for 2011-2012.

ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) attended a U.S. Food and Drug Administration (FDA)–sponsored workshop to address growing concerns regarding drug shortages in certain sectors of the pharmaceutical industry September 26.

This month, Florida and California are recognizing "Plasma Protein Therapies Month," by raising awareness for the valuable contributions of plasma donors and for the rare, genetic diseases treated with the therapies that are made possible through plasma donation.

BRUSSELS, BELGIUM - The Plasma Protein Therapeutics Association (PPTA) welcomes the findings of the ConQuaestor report on the financing of Sanquin, the Dutch National Fractionator.

ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) believes the Internal Revenue Services' issuance of temporary and proposed regulations implementing the annual pharmaceutical fee undermines patients with rare diseases and fails to take into account concerns expressed by leading consumer organizations and Congress.

ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) recommends that the Centers for Medicare and Medicaid Services (CMS) take necessary steps to improve drug reimbursement under the Hospital Outpatient Perspective Payment System (OPPS).

ANNAPOLIS, MD - The Plasma Protein Therapeutics Association (PPTA) applauds the introduction of bipartisan legislation, the Preserving Access to Orphan Drugs Act (H.R. 2672) and (S. 1423), which will safeguard the development of drugs and therapies that treat patients with rare diseases by eliminating barriers to innovation.

ANNAPOLIS, MD - PPTA opposes New Jersey Assembly Bill 2003 passed by the New Jersey Assembly Appropriations Committee on June 13 that imposes a new tax on therapies used to treat bleeding disorders like hemophilia.